{
  "cik": 1807120,
  "cik_padded": "0001807120",
  "entityName": "Design Therapeutics, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-098491",
      "filed": "2026-03-09",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 193000.0,
        "cash": 16856000.0,
        "eps_diluted": -1.22,
        "free_cash_flow": -54551000.0,
        "net_income": -69792000.0,
        "operating_cash_flow": -54358000.0,
        "operating_income": -79467000.0,
        "stockholders_equity": 212503000.0,
        "total_assets": 226203000.0,
        "total_liabilities": 13700000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.06446967807513306,
        "roa_avg2y": -0.2918360178634151,
        "roa_period_end": -0.3085370220554104,
        "roe_avg2y": -0.30704795424549053,
        "roe_period_end": -0.32842830454158295
      }
    },
    {
      "accn": "0001193125-26-098491",
      "filed": "2026-03-09",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 340000.0,
        "cash": 22563000.0,
        "eps_diluted": -0.88,
        "free_cash_flow": -43445000.0,
        "net_income": -49588000.0,
        "operating_cash_flow": -43105000.0,
        "operating_income": -62383000.0,
        "stockholders_equity": 242097000.0,
        "total_assets": 252093000.0,
        "total_liabilities": 9996000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.041289235306509374,
        "roa_avg2y": -0.18307072079389222,
        "roa_period_end": -0.19670518419789523,
        "roe_avg2y": -0.19080233327689963,
        "roe_period_end": -0.20482699083425238
      }
    },
    {
      "accn": "0001193125-26-098491",
      "filed": "2026-03-09",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 256000.0,
        "cash": 21200000.0,
        "eps_diluted": -1.19,
        "free_cash_flow": -58816000.0,
        "net_income": -66862000.0,
        "operating_cash_flow": -58560000.0,
        "operating_income": -78190000.0,
        "stockholders_equity": 277687000.0,
        "total_assets": 289643000.0,
        "total_liabilities": 11956000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.04305567059314984,
        "roa_avg2y": -0.2119978439392498,
        "roa_period_end": -0.23084279613178982,
        "roe_avg2y": -0.2210325009876082,
        "roe_period_end": -0.24078188752084181
      }
    },
    {
      "accn": "0000950170-25-035910",
      "filed": "2025-03-10",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 918000.0,
        "cash": 26500000.0,
        "eps_diluted": -1.14,
        "free_cash_flow": -52235000.0,
        "net_income": -63308000.0,
        "operating_cash_flow": -51317000.0,
        "operating_income": -67593000.0,
        "stockholders_equity": 327310000.0,
        "total_assets": 341137000.0,
        "total_liabilities": 13827000.0
      },
      "period_end": "2022-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.04224435550395649,
        "roa_avg2y": -0.17304501608595943,
        "roa_period_end": -0.18557940065135126,
        "roe_avg2y": -0.17847316193053675,
        "roe_period_end": -0.19341908282667808
      }
    },
    {
      "accn": "0000950170-24-033492",
      "filed": "2024-03-19",
      "fiscal_year": 2021,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 1538000.0,
        "cash": 298569000.0,
        "eps_diluted": -0.77,
        "free_cash_flow": -30915000.0,
        "net_income": -35533000.0,
        "operating_cash_flow": -29377000.0,
        "operating_income": -35831000.0,
        "stockholders_equity": 382130000.0,
        "total_assets": 390557000.0,
        "total_liabilities": 8427000.0
      },
      "period_end": "2021-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.02205270457697642,
        "roa_avg2y": -0.1664024651523276,
        "roa_period_end": -0.09098031785373198,
        "roe_avg2y": -0.1916481264242277,
        "roe_period_end": -0.09298667992567974
      }
    },
    {
      "accn": "0000950170-23-007869",
      "filed": "2023-03-14",
      "fiscal_year": 2020,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 76000.0,
        "cash": 2379000.0,
        "free_cash_flow": -8745000.0,
        "net_income": -8280000.0,
        "operating_cash_flow": -8669000.0,
        "operating_income": -8330000.0,
        "stockholders_equity": -11315000.0,
        "total_assets": 36516000.0,
        "total_liabilities": 2475000.0
      },
      "period_end": "2020-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.22674991784423265,
        "roe_avg2y": 1.1071738985090593
      }
    },
    {
      "accn": "0000950170-22-003369",
      "filed": "2022-03-10",
      "fiscal_year": 2019,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -3642000.0
      },
      "period_end": "2019-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-098491",
    "filed": "2026-03-09",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001807120.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001807120.json"
  },
  "ticker": "DSGN"
}